{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:48:24Z","timestamp":1790984904942,"version":"4.1.0"},"reference-count":77,"publisher":"Oxford University Press (OUP)","issue":"929","license":[{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Forty years on from its worldwide withdrawal, thalidomide is currently undergoing a remarkable renaissance as a novel and powerful immunomodulatory agent. Over the last decade it has been found to be active in a wide variety of inflammatory and malignant disorders where conventional therapies have failed. Recently, considerable progress has been made in elucidating its complex mechanisms of action, which include both anticytokine and antiangiogenic properties. However, in addition to its well known teratogenic potential, it has a significant side effect profile that leads to cessation of treatment in up to 30% of subjects. In response to this, two new classes of potentially safer and non-teratogenic derivatives have recently been developed. This review summarises the biological effects, therapeutic applications, safety profile, and future potential of thalidomide and its derivatives.<\/jats:p>","DOI":"10.1136\/pmj.79.929.127","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T23:08:34Z","timestamp":1050448114000},"page":"127-132","source":"Crossref","is-referenced-by-count":66,"title":["Thalidomide and its derivatives: emerging from the wilderness"],"prefix":"10.1093","volume":"79","author":[{"given":"J N","family":"Gordon","sequence":"first","affiliation":[{"name":"Division of Infection, Inflammation, and Repair, University of Southampton, Southampton General Hospital , Southampton"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P M","family":"Goggin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Queen Alexandra Hospital , Portsmouth"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2003,3,1]]},"reference":[{"key":"2023042409411901000_R1","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(61)90927-8","article-title":"Thalidomide and congenital abnormalities.","volume":"ii","author":"McBride","year":"1961","journal-title":"Lancet"},{"key":"2023042409411901000_R2","first-page":"2555","article-title":"Fragen aus der Praxis: kindliche Missbildungen nach Medikament Einnahme wahrend der Graviditat?","volume":"86","author":"Lenz","year":"1961","journal-title":"Dtsch Med Wochenschr"},{"key":"2023042409411901000_R3","first-page":"183","article-title":"Further observation with thalidomide in lepra reactions.","volume":"36","author":"Sheskin","year":"1965","journal-title":"Lepr Rev"},{"key":"2023042409411901000_R4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1084\/jem.173.3.699","article-title":"Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.","volume":"173","author":"Sampaio","year":"1991","journal-title":"J Exp Med"},{"key":"2023042409411901000_R5","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1248\/cpb.42.1157","article-title":"(S)-form of alpha-methyl-N(alpha)- phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-alpha production by human leukemia cell HL-60: implication of optical resolution of thalidomidal effects.","volume":"42","author":"Nishimura","year":"1994","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"2023042409411901000_R6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1023\/A:1021008016719","article-title":"A double-blind study of the sedative effects of the thalidomide enantiomers in humans.","volume":"26","author":"Hoglund","year":"1998","journal-title":"J Pharmacokinet Biopharm"},{"key":"2023042409411901000_R7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/215296a0","article-title":"Toxicity and teratogenicity of optical isomers of thalidomide.","volume":"215","author":"Fabro","year":"1967","journal-title":"Nature"},{"key":"2023042409411901000_R8","first-page":"1640","article-title":"Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers.","volume":"29","author":"Blaschke","year":"1979","journal-title":"Arzneimittelforschung"},{"key":"2023042409411901000_R9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s002280100320","article-title":"Clinical pharmacology of thalidomide.","volume":"57","author":"Eriksson","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"2023042409411901000_R10","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0009-9236(98)90050-9","article-title":"Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone.","volume":"64","author":"Trapnell","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"2023042409411901000_R11","first-page":"1355","article-title":"Thalidomide is distributed into human semen after oral dosing.","volume":"29","author":"Teo","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"2023042409411901000_R12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0162-3109(98)00010-1","article-title":"Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells.","volume":"40","author":"Rowland","year":"1998","journal-title":"Immunopharmacology"},{"key":"2023042409411901000_R13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0165-2478(99)00055-3","article-title":"Selective down-regulation of T cell- and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone.","volume":"68","author":"Rowland","year":"1999","journal-title":"Immunol Lett"},{"key":"2023042409411901000_R14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0954-6111(97)90134-7","article-title":"Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages.","volume":"91","author":"Tavares","year":"1997","journal-title":"Respir Med"},{"key":"2023042409411901000_R15","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/gut.50.2.196","article-title":"Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn\u2019s disease.","volume":"50","author":"Bauditz","year":"2002","journal-title":"Gut"},{"key":"2023042409411901000_R16","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/infdis\/172.4.1137","article-title":"Thalidomide inhibits tumor necrosis factor-alpha production by lipopolysaccharide- and lipoarabinomannan-stimulated human microglial cells.","volume":"172","author":"Peterson","year":"1995","journal-title":"J Infect Dis"},{"key":"2023042409411901000_R17","doi-asserted-by":"crossref","first-page":"I107","DOI":"10.1136\/ard.58.2008.i107","article-title":"Immunomodulation by thalidomide and thalidomide analogues.","volume":"58","author":"Corral","year":"1999","journal-title":"Ann Rheum Dis"},{"key":"2023042409411901000_R18","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1084\/jem.177.6.1675","article-title":"Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.","volume":"77","author":"Moreira","year":"1993","journal-title":"J Exp Med"},{"key":"2023042409411901000_R19","doi-asserted-by":"crossref","first-page":"22382","DOI":"10.1074\/jbc.M100938200","article-title":"Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity.","volume":"276","author":"Keifer","year":"2001","journal-title":"J Biol Chem"},{"key":"2023042409411901000_R20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/08923979609007110","article-title":"Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells.","volume":"18","author":"Shannon","year":"1996","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"2023042409411901000_R21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-2249.1995.tb05527.x","article-title":"The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures.","volume":"99","author":"McHugh","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"2023042409411901000_R22","doi-asserted-by":"crossref","first-page":"5157","DOI":"10.4049\/jimmunol.159.10.5157","article-title":"Inhibition of IL-12 production by thalidomide.","volume":"159","author":"Moller","year":"1997","journal-title":"J Immunol"},{"key":"2023042409411901000_R23","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1089\/088922299310269","article-title":"Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients.","volume":"15","author":"Haslett","year":"1999","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2023042409411901000_R24","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.4049\/jimmunol.168.10.4914","article-title":"Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity.","volume":"168","author":"Dredge","year":"2002","journal-title":"J Immunol"},{"key":"2023042409411901000_R25","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis.","volume":"91","author":"D\u2019Amato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023042409411901000_R26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s004170050106","article-title":"Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor.","volume":"236","author":"Kruse","year":"1998","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2023042409411901000_R27","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1006\/exer.1997.0292","article-title":"Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization.","volume":"64","author":"Kenyon","year":"1997","journal-title":"Exp Eye Res"},{"key":"2023042409411901000_R28","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.","volume":"163","author":"Corral","year":"1999","journal-title":"J Immunol"},{"key":"2023042409411901000_R29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1365-2249.1999.01039.x","article-title":"Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis.","volume":"118","author":"Oliver","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"2023042409411901000_R30","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.4049\/jimmunol.161.8.4236","article-title":"CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production.","volume":"161","author":"Marriott","year":"1998","journal-title":"J Immunol"},{"key":"2023042409411901000_R31","first-page":"719","article-title":"WHO co-ordinated short-term double- blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients.","volume":"45","author":"Iyer","year":"1971","journal-title":"Bull World Health Organ"},{"key":"2023042409411901000_R32","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-4362.1980.tb00342.x","article-title":"The treatment of lepra reaction in lepromatous leprosy. Fifteen years\u2019 experience with thalidomide.","volume":"19","author":"Sheskin","year":"1980","journal-title":"Int J Dermatol"},{"key":"2023042409411901000_R33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0753-3322(01)00147-0","article-title":"Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro.","volume":"56","author":"Sampaio","year":"2002","journal-title":"Biomed Pharmacother"},{"key":"2023042409411901000_R34","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archderm.1990.01670310085012","article-title":"Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis.","volume":"126","author":"Revuz","year":"1990","journal-title":"Arch Dermatol"},{"key":"2023042409411901000_R35","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199705223362103","article-title":"Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.","volume":"336","author":"Jacobson","year":"1997","journal-title":"N Engl J Med"},{"key":"2023042409411901000_R36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1086\/314834","article-title":"Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group.","volume":"180","author":"Jacobson","year":"1999","journal-title":"J Infect Dis"},{"key":"2023042409411901000_R37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0753-3322(01)00154-8","article-title":"Thalidomide in Beh\u00e7et\u2019s disease.","volume":"56","author":"Shek","year":"2002","journal-title":"Biomed Pharmacother"},{"key":"2023042409411901000_R38","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Beh\u00e7et syndrome. A randomized, double-blind, placebo- controlled trial.","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann Intern Med"},{"key":"2023042409411901000_R39","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/bmj.1.6166.792","article-title":"Treatment of ulcerative colitis with thalidomide.","volume":"i","author":"Waters","year":"1979","journal-title":"BMJ"},{"key":"2023042409411901000_R40","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0016-5085(99)70276-3","article-title":"Thalidomide therapy for patients with refractory Crohn\u2019s disease: an open-label trial.","volume":"117","author":"Ehrenpreis","year":"1999","journal-title":"Gastroenterology"},{"key":"2023042409411901000_R41","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0016-5085(99)70277-5","article-title":"An open-label pilot study of low- dose thalidomide in chronically active, steroid-dependent Crohn\u2019s disease.","volume":"117","author":"Vasiliauskas","year":"1999","journal-title":"Gastroenterology"},{"key":"2023042409411901000_R42","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1440-1746.2002.02564.x","article-title":"Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease.","volume":"17","author":"Bariol","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"2023042409411901000_R43","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1046\/j.1365-2036.2002.01273.x","article-title":"An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn\u2019s disease.","volume":"16","author":"Sabate","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"2023042409411901000_R44","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1089\/08892220050140892","article-title":"Thalidomide for the treatment of AIDS-associated wasting.","volume":"16","author":"Kaplan","year":"2000","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2023042409411901000_R45","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/BF03401576","article-title":"Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis.","volume":"1","author":"Tramontana","year":"1995","journal-title":"Mol Med"},{"issue":"II","key":"2023042409411901000_R46","first-page":"A4","article-title":"Oesophageal cancer and cachexia: the effects of thalidomide on weight loss and lean body mass in a sequential (metabolic) study.","volume":"50","author":"Khan","year":"2002","journal-title":"Gut"},{"key":"2023042409411901000_R47","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/00003495-200060020-00003","article-title":"Potential novel uses of thalidomide: focus on palliative care.","volume":"60","author":"Peuckmann","year":"2000","journal-title":"Drugs"},{"key":"2023042409411901000_R48","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma.","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"2023042409411901000_R49","doi-asserted-by":"crossref","first-page":"813","DOI":"10.4065\/77.8.813","article-title":"Current therapy for multiple myeloma.","volume":"77","author":"Rajkumar","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"2023042409411901000_R50","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/10428190290006224","article-title":"Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma.","volume":"43","author":"Dmoszynska","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"2023042409411901000_R51","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1182\/blood.V100.6.2263","article-title":"Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma.","volume":"100","author":"Neben","year":"2002","journal-title":"Blood"},{"key":"2023042409411901000_R52","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood.V98.4.958","article-title":"Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.","volume":"98","author":"Raza","year":"2001","journal-title":"Blood"},{"key":"2023042409411901000_R53","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0753-3322(01)00146-9","article-title":"Thalidomide in cancer.","volume":"56","author":"Singhal","year":"2002","journal-title":"Biomed Pharmacother"},{"key":"2023042409411901000_R54","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0140-6736(00)02586-1","article-title":"Effect of thalidomide on gastrointestinal toxic effects of irinotecan.","volume":"356","author":"Govindarajan","year":"2000","journal-title":"Lancet"},{"key":"2023042409411901000_R55","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0002-9343(02)01300-1","article-title":"Thalidomide-associated deep vein thrombosis and pulmonary embolism.","volume":"113","author":"Bennett","year":"2002","journal-title":"Am J Med"},{"key":"2023042409411901000_R56","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0190-9622(96)90122-X","article-title":"Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses.","volume":"35","author":"Tseng","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"2023042409411901000_R57","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis.","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"2023042409411901000_R58","first-page":"393","article-title":"Thalidomide for treatment of graft-versus-host disease.","volume":"3","author":"Vogelsang","year":"1988","journal-title":"Bone Marrow Transplant"},{"key":"2023042409411901000_R59","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.bmt.1702626","article-title":"Response to thalidomide therapy in refractory chronic graft-versus-host disease.","volume":"26","author":"Browne","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"2023042409411901000_R60","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1056\/NEJM199204163261604","article-title":"Thalidomide for the treatment of chronic graft-versus-host disease.","volume":"326","author":"Vogelsang","year":"1992","journal-title":"N Engl J Med"},{"key":"2023042409411901000_R61","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/bbmt.2001.v7.pm11400948","article-title":"Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease.","volume":"7","author":"Arora","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023042409411901000_R62","first-page":"964","article-title":"The effect of thalidomide and 2 analogs on collagen induced arthritis.","volume":"25","author":"Oliver","year":"1998","journal-title":"J Rheumatol"},{"key":"2023042409411901000_R63","first-page":"158","article-title":"Treatment of refractory rheumatoid arthritis--the thalidomide experience.","volume":"16","author":"Gutierrez-Rodriguez","year":"1989","journal-title":"J Rheumatol"},{"key":"2023042409411901000_R64","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1136\/ard.55.11.833","article-title":"An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis.","volume":"55","author":"Huizinga","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"2023042409411901000_R65","first-page":"2344","article-title":"Thalidomide in the treatment of refractory rheumatoid arthritis.","volume":"26","author":"Keesal","year":"1999","journal-title":"J Rheumatol"},{"key":"2023042409411901000_R66","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1378\/chest.122.1.227","article-title":"Thalidomide for chronic sarcoidosis.","volume":"122","author":"Baughman","year":"2002","journal-title":"Chest"},{"key":"2023042409411901000_R67","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1006\/clim.2000.4920","article-title":"Immune stimulation in scleroderma patients treated with thalidomide.","volume":"97","author":"Oliver","year":"2000","journal-title":"Clin Immunol"},{"key":"2023042409411901000_R68","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/rheumatology\/36.3.353","article-title":"Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients.","volume":"36","author":"Stevens","year":"1997","journal-title":"Br J Rheumatol"},{"key":"2023042409411901000_R69","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0890-6238(99)00053-2","article-title":"Differential alteration by thalidomide of the glutathione content of rat vs rabbit conceptuses in vitro.","volume":"13","author":"Hansen","year":"1999","journal-title":"Reprod Toxicol"},{"key":"2023042409411901000_R70","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0095-5108(18)30810-8","article-title":"The thalidomide syndrome: risks of exposure and spectrum of malformations.","volume":"13","author":"Newman","year":"1986","journal-title":"Clin Perinatol"},{"key":"2023042409411901000_R71","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/1096-9926(200012)62:6<432::AID-TERA11>3.0.CO;2-Z","article-title":"The re-emergence of thalidomide: results of a scientific conference.","volume":"62","author":"Neiger","year":"2000","journal-title":"Teratology"},{"key":"2023042409411901000_R72","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/8466","article-title":"Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity.","volume":"5","author":"Parman","year":"1999","journal-title":"Nat Med"},{"key":"2023042409411901000_R73","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0024-3205(00)00636-6","article-title":"A possible role of N-cadherin in thalidomide teratogenicity.","volume":"67","author":"Thiele","year":"2000","journal-title":"Life Sci"},{"key":"2023042409411901000_R74","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/(SICI)1096-9926(200003)61:3<189::AID-TERA6>3.0.CO;2-W","article-title":"Hypothesis: thalidomide embryopathy-proposed mechanism of action.","volume":"61","author":"Stephens","year":"2000","journal-title":"Teratology"},{"key":"2023042409411901000_R75","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/mus.1109","article-title":"Thalidomide neuropathy in patients treated for metastatic prostate cancer.","volume":"24","author":"Molloy","year":"2001","journal-title":"Muscle Nerve"},{"key":"2023042409411901000_R76","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archderm.1994.01690010070009","article-title":"Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients.","volume":"130","author":"Ochonisky","year":"1994","journal-title":"Arch Dermatol"},{"key":"2023042409411901000_R77","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/pgmj.70.830.901","article-title":"Guideline for the clinical use and dispensing of thalidomide.","volume":"70","author":"Powell","year":"1994","journal-title":"Postgrad Med J"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/79\/929\/127\/50038966\/postgradmedj-79-127.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/79\/929\/127\/50038966\/postgradmedj-79-127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T09:58:51Z","timestamp":1682330331000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/79\/929\/127\/7045544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3,1]]},"references-count":77,"journal-issue":{"issue":"929","published-online":{"date-parts":[[2003,3,1]]},"published-print":{"date-parts":[[2003,3,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pmj.79.929.127","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2003,3]]},"published":{"date-parts":[[2003,3,1]]}}}